Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid,

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid, Date of authorisation: 02/04/2019, Revision: 11, Status: Authorised